Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Rochester, Minnesota

This page shows live ClinicalTrials.gov search results for Rochester, Minnesota, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
9154
Shown on this page
12
Current sort
Recently updated
Location scope
Rochester, MN
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Rochester, Minnesota. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 793–804 of 9,154 matching trials in Rochester, MN.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Rochester

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Recruiting Phase 2 Interventional

Ulixertinib in People With Histiocytic Neoplasms

NCT06411821
View directory record Official record
Conditions
Histiocytic Neoplasms
Interventions
Ulixertinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Rochester, Minnesota • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 15, 2026, 9:11 AM EST
Temporarily Not Available No phase listed Expanded access

Expanded Access to Cyclic Irrigation in Patients Undergoing Exchange Arthroplasty

NCT06383611
View directory record Official record
Conditions
Prosthetic-joint Infection
Interventions
VT-X7 Treatment System
Combination Product
Lead sponsor
Osteal Therapeutics, Inc.
Industry
Eligibility
22 Years to 84 Years
U.S. locations
14
States / cities
Phoenix, Arizona • Los Angeles, California • Grand Junction, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 15, 2026, 9:11 AM EST
Active, not recruiting Phase 2 Interventional

Iptacopan in Patients With ANCA Associated Vasculitis

NCT06388941
View directory record Official record
Conditions
Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
Interventions
Iptacopan, Placebo, Rituximab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Mesa, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 15, 2026, 9:11 AM EST
Active, not recruiting Not applicable Interventional Results available

Acute Recording of Stereotyped High-Frequency Oscillations

NCT05439655
View directory record Official record
Conditions
Epilepsy
Interventions
Brain Interchange System
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
3 Years to 64 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Rochester, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 15, 2026, 9:11 AM EST
Completed Not applicable Interventional

Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial

NCT06037863
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Best Practice, Computed Tomography, Electronic Health Record Review, Imaging Procedure, Questionnaire Administration, Radiation Therapy
Other · Procedure · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 15, 2026, 9:11 AM EST
Active, not recruiting Phase 3 Interventional

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

NCT07087054
View directory record Official record
Conditions
Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum, Carcinoid Tumor of Cecum, Carcinoid Tumor of Liver, Carcinoid Tumor of Pancreas, Carcinoid Syndrome Diarrhea, Carcinoid Intestine Tumor
Interventions
Paltusotine, Placebo
Drug
Lead sponsor
Crinetics Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
17
States / cities
Gilbert, Arizona • Newport Beach, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 15, 2026, 9:11 AM EST
Recruiting Phase 3 Interventional

A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to Moderate Lumbar Degenerative Disc Disease

NCT07254806
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
IDCT (rebonuputemcel), Sham (No Treatment)
Biological · Other
Lead sponsor
DiscGenics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 15, 2026, 9:11 AM EST
Active, not recruiting Phase 3 Interventional

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

NCT07288398
View directory record Official record
Conditions
Pulmonary Hypertension Associated With HFpEF
Interventions
TNX-103, Placebo
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
45
States / cities
Alexander City, Alabama • Tucson, Arizona • Sacramento, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 15, 2026, 9:11 AM EST
Active, not recruiting Phase 1Phase 2 Interventional Results available

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

NCT03126630
View directory record Official record
Conditions
Pleural Malignant Mesothelioma
Interventions
Anetumab Ravtansine, Laboratory Biomarker Analysis, Pembrolizumab, Pharmacological Study
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 15, 2026, 9:11 AM EST
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy

NCT07498426
View directory record Official record
Conditions
Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
Interventions
NIO752, Placebo
Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
41 Years to 81 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
9
States / cities
Scottsdale, Arizona • San Francisco, California • Englewood, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 15, 2026, 9:11 AM EST
Recruiting Not applicable Interventional

Renal Pelvic Denervation Pilot Trial

NCT07005050
View directory record Official record
Conditions
Uncontrolled Hypertension
Interventions
RPD, Active hypertension medical therapy
Device · Drug
Lead sponsor
Verve Medical, Inc
Industry
Eligibility
21 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
9
States / cities
Birmingham, Alabama • Surprise, Arizona • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 15, 2026, 9:11 AM EST
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

NCT06659640
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia
Interventions
ALN-6400, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
8
States / cities
Birmingham, Alabama • Cypress, California • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 15, 2026, 9:11 AM EST